Author of

• 25949

  +

  P2.12 - Small Cell Lung Cancer/NET (Not CME Accredited Session) (ID 961)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall

  • 27159

    +

    P2.12-06 - The Efficacy of Apatinib Plus Topotecan as Laterline Therapy for Advanced Small Cell Lung Cancer (ID 13099)

    16:45 - 18:00  |  Presenting Author(s): Haifeng Qin
    • Abstract
    • Slides

    Background
    

    Small cell lung cancer（SCLC） is a malignant, aggressive and rapidly progressing cancer. There is no standard treatment strategy for patients with advanced SCLC who experienced progression with first line of chemotherapy. Apatinib, an oral tyrosine kinaese inhibitor targeting vascular endothelial growth receptor 2 (VEGFR 2), has shown well anti-tumor activity and manageable toxicities in SCLC. Some previous cases showed that apatinib plus topotecan for laterline therapy for advanced SCLC patients is safe and effective, but there is no similar studies at home and abroad.Small cell lung cancer（SCLC） is a malignant, aggressive and rapidly progressing cancer. There is no standard treatment strategy for patients with advanced SCLC who experienced progression with first line of chemotherapy. Apatinib, an oral tyrosine kinaese inhibitor targeting vascular endothelial growth receptor 2 (VEGFR 2), has shown well anti-tumor activity and manageable toxicities in SCLC. Some previous cases showed that apatinib plus topotecan for laterline therapy for advanced SCLC patients is safe and effective, but there is no similar studies at home and abroad.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    Our study retrospectively assessed the efficacy and safety of apatinib plus topotecan in patients with advanced SCLC after the first line of chemotherapy. The primary endpoint was progression free survival (PFS). The study was expected to enroll 25 patients who received apatinib (250mg QD) plus topotecan (2mg QD; day1-5, every four weeks). Treatment was continued until disease progression and the tumor response was determined according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

    4c3880bb027f159e801041b1021e88e8 Result
    

    The main results are showed as follows.

    

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Apatinib plus topotecan exhibits superior activity and generally manageable toxicities for the pretreated patients with advanced small cell lung cancer. It may provide a new therapy strategy for them, but large sample and additional clinical trials are also needed.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.